These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

496 related articles for article (PubMed ID: 27059553)

  • 1. Safety and clinical activity of vascular endothelial growth factor receptor (VEGFR)-tyrosine kinase inhibitors after programmed cell death 1 inhibitor treatment in patients with metastatic clear cell renal cell carcinoma.
    Nadal R; Amin A; Geynisman DM; Voss MH; Weinstock M; Doyle J; Zhang Z; Viudez A; Plimack ER; McDermott DF; Motzer R; Rini B; Hammers HJ
    Ann Oncol; 2016 Jul; 27(7):1304-11. PubMed ID: 27059553
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Association Between PD-L1 Expression and the Clinical Outcomes to Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma.
    Shin SJ; Jeon YK; Cho YM; Lee JL; Chung DH; Park JY; Go H
    Oncologist; 2015 Nov; 20(11):1253-60. PubMed ID: 26424759
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of everolimus in patients with advanced renal cell carcinoma refractory or intolerant to VEGFR-TKIs and safety compared with prior VEGFR-TKI treatment.
    Kato R; Obara W; Matsuura T; Kato Y; Iwasaki K; Fujioka T
    Jpn J Clin Oncol; 2014 May; 44(5):479-85. PubMed ID: 24688083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Everolimus in metastatic renal cell carcinoma: Subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study.
    Calvo E; Escudier B; Motzer RJ; Oudard S; Hutson TE; Porta C; Bracarda S; Grünwald V; Thompson JA; Ravaud A; Kim D; Panneerselvam A; Anak O; Figlin RA
    Eur J Cancer; 2012 Feb; 48(3):333-9. PubMed ID: 22209391
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lenvatinib with or Without Everolimus in Patients with Metastatic Renal Cell Carcinoma After Immune Checkpoint Inhibitors and Vascular Endothelial Growth Factor Receptor-Tyrosine Kinase Inhibitor Therapies.
    Wiele AJ; Bathala TK; Hahn AW; Xiao L; Duran M; Ross JA; Jonasch E; Shah AY; Campbell MT; Msaouel P; Tannir NM
    Oncologist; 2021 Jun; 26(6):476-482. PubMed ID: 33792094
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The efficacy of subsequent therapy after failure of anti-PD-1 antibody in metastatic renal cell carcinoma.
    Zhou Y; Ma B; Gao Q; Zhao L
    Transl Cancer Res; 2024 May; 13(5):2238-2250. PubMed ID: 38881916
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.
    Shah AY; Kotecha RR; Lemke EA; Chandramohan A; Chaim JL; Msaouel P; Xiao L; Gao J; Campbell MT; Zurita AJ; Wang J; Corn PG; Jonasch E; Motzer RJ; Sharma P; Voss MH; Tannir NM
    Eur J Cancer; 2019 Jun; 114():67-75. PubMed ID: 31075726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and efficacy of everolimus in Chinese patients with metastatic renal cell carcinoma resistant to vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy: an open-label phase 1b study.
    Guo J; Huang Y; Zhang X; Zhou F; Sun Y; Qin S; Ye Z; Wang H; Jappe A; Straub P; Pirotta N; Gogov S
    BMC Cancer; 2013 Mar; 13():136. PubMed ID: 23514360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.
    Park I; Lee JL; Ahn JH; Lee DH; Lee KH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H
    Cancer Chemother Pharmacol; 2015 May; 75(5):1025-35. PubMed ID: 25776906
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma.
    Barata PC; De Liano AG; Mendiratta P; Crolley V; Szabados B; Morrison L; Wood L; Allman K; Tyler A; Martin A; Gilligan T; Grivas P; Ornstein M; Garcia JA; Powles T; Rini BI
    Br J Cancer; 2018 Jul; 119(2):160-163. PubMed ID: 29795307
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Everolimus in metastatic renal cell carcinoma patients intolerant to previous VEGFr-TKI therapy: a RECORD-1 subgroup analysis.
    Bracarda S; Hutson TE; Porta C; Figlin RA; Calvo E; Grünwald V; Ravaud A; Motzer R; Kim D; Anak O; Panneerselvam A; Escudier B
    Br J Cancer; 2012 Apr; 106(9):1475-80. PubMed ID: 22441644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase 2 Study of Bevacizumab and Temsirolimus After VEGFR TKI in Metastatic Renal Cell Carcinoma.
    Mahoney KM; Jacobus S; Bhatt RS; Song J; Carvo I; Cheng SC; Simpson M; Fay AP; Puzanov I; Michaelson MD; Atkins MB; McDermott DF; Signoretti S; Choueiri TK
    Clin Genitourin Cancer; 2016 Aug; 14(4):304-313.e6. PubMed ID: 27036973
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.
    Koo DH; Park I; Ahn JH; Lee DH; You D; Jeong IG; Song C; Hong B; Hong JH; Ahn H; Lee JL
    Cancer Chemother Pharmacol; 2016 Feb; 77(2):339-47. PubMed ID: 26687171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Everolimus after failure of one prior VEGF-targeted therapy in metastatic renal cell carcinoma: Final results of the MARC-2 trial.
    Staehler M; Stöckle M; Christoph DC; Stenzl A; Potthoff K; Grimm MO; Klein D; Harde J; Brüning F; Goebell PJ; Augustin M; Roos F; Benz-Rüd I; Marschner N; Grünwald V
    Int J Cancer; 2021 Apr; 148(7):1685-1694. PubMed ID: 33070307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of single-agent bevacizumab in patients with metastatic renal cell carcinoma previously treated with vascular endothelial growth factor tyrosine kinase inhibitors.
    Turnbull JD; Cobert J; Jaffe T; Harrison MR; George DJ; Armstrong AJ
    Clin Genitourin Cancer; 2013 Mar; 11(1):45-50. PubMed ID: 23041453
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy.
    Grünwald V; Karakiewicz PI; Bavbek SE; Miller K; Machiels JP; Lee SH; Larkin J; Bono P; Rha SY; Castellano D; Blank CU; Knox JJ; Hawkins R; Anak O; Rosamilia M; Booth J; Pirotta N; Bodrogi I;
    Eur J Cancer; 2012 Feb; 48(3):324-32. PubMed ID: 21803569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nivolumab, nivolumab-ipilimumab, and VEGFR-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
    Vano YA; Elaidi R; Bennamoun M; Chevreau C; Borchiellini D; Pannier D; Maillet D; Gross-Goupil M; Tournigand C; Laguerre B; Barthélémy P; Coquan E; Gravis G; Houede N; Cancel M; Huillard O; Beuzeboc P; Fournier L; Méjean A; Cathelineau X; Doumerc N; Paparel P; Bernhard JC; de la Taille A; Bensalah K; Tricard T; Waeckel T; Pignot G; Braychenko E; Caruso S; Sun CM; Verkarre V; Lacroix G; Moreira M; Meylan M; Bougouïn A; Phan L; Thibault-Carpentier C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C; Oudard S
    Lancet Oncol; 2022 May; 23(5):612-624. PubMed ID: 35390339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Second-line targeted therapies after nivolumab-ipilimumab failure in metastatic renal cell carcinoma.
    Auvray M; Auclin E; Barthelemy P; Bono P; Kellokumpu-Lehtinen P; Gross-Goupil M; De Velasco G; Powles T; Mouillet G; Vano YA; Gravis G; Mourey L; Priou F; Rolland F; Escudier B; Albiges L
    Eur J Cancer; 2019 Feb; 108():33-40. PubMed ID: 30616146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of Response Classifier for Vascular Endothelial Growth Factor Receptor (VEGFR)-Tyrosine Kinase Inhibitor (TKI) in Metastatic Renal Cell Carcinoma.
    Go H; Kang MJ; Kim PJ; Lee JL; Park JY; Park JM; Ro JY; Cho YM
    Pathol Oncol Res; 2019 Jan; 25(1):51-58. PubMed ID: 28963640
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of targeted therapies after PD-1/PD-L1 blockade in metastatic renal cell carcinoma.
    Albiges L; Fay AP; Xie W; Krajewski K; McDermott DF; Heng DY; Dariane C; DeVelasco G; Lester R; Escudier B; Choueiri TK
    Eur J Cancer; 2015 Nov; 51(17):2580-6. PubMed ID: 26346135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.